Clinical trials: Epidermal Growth Factor Receptor
Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Leptomeningeal metastasis (LM) is a complication of advanced non-small cell lung cancer (NSCLC). The incidence of LM in NSCLC patients is around 3-5 %, reaching 9.4 % of those with an epidermal growth factor receptor (EGFR)…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis
- Trial name
- NCT05805631
- Testing
- Pemetrexed
- Where
- Taiwan
- Volunteers
- 23 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism)
A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
This study aims to explore the clinical outcomes of Comprehensive Enhanced Preventive Management (CEPM) combined with an amivantamab-containing treatment regimen in Chinese patients with EGFR-mutated advanced NSCLC.
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors, Infusion Reaction
- Trial name
- AmiCARE (NCT07469488)
- Testing
- Enhanced dermatologic management, Enhanced IRR Prophylaxis, Enhanced VTE Prophylaxis (Cohort 1 only)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
This is a non-randomized, open-label, single-arm, multicenter, phase II study of palbociclib in combination with tamoxifen in women with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anticancer…
- Conditions
- Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor
- Trial name
- NCT02668666
- Testing
- Palbociclib, Tamoxifen
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Oana Danciu, MD
Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
To find out if the combination of repotrectinib and fulvestrant can control the disease in participants with metastatic invasive lobular carcinoma.
- Trial name
- NCT06408168
- Testing
- Fulvestrant, Repotrectinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor
Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)
This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have…
- Trial name
- BOOST (NCT07073365)
- Testing
- Local Therapy (Surgery or Radiotherapy)
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Pusan National University Hospital
Solid Tumor, Solid Tumor, Adult
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of…
- Conditions
- Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor
- Trial name
- NCT06264921
- Testing
- NKT3447
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- NiKang Therapeutics, Inc.
Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal adenocarcinoma than standard…
- Conditions
- Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach, Epidermal Growth Factor Receptor (EGFR) Protein Overexpression
- Trial name
- INNOVATION (NCT02205047)
- Testing
- Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab
- Where
- 48 sites in Belgium, Estonia and 11 more
- Volunteers
- 172 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
Medical Access Program for Patritumab Deruxtecan
The purpose of this Medical Access Program is to provide access to HER3-DXd for eligible patients with NSCLC who, in their treating physician's opinion, have an unmet clinical need which cannot be treated with approved and…
- Trial name
- NCT06099639
- Testing
- HER3-DXd
- Where
- 21 sites in United States
- Sponsor
- Daiichi Sankyo
HER2 Amplified, Advanced Breast Cancer
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
The purpose of this study was to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.
- Conditions
- HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
- Trial name
- NCT02091960
- Testing
- Enzalutamide, Trastuzumab
- Where
- 39 sites in United States, Belgium and 4 more
- Volunteers
- 103 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
This is an open-label, single-arm, phase I trial. It is designed with a conservative dose escalation plan to ensure patient's safety and with a strong translational component to inform if target inhibition is achieved.
- Conditions
- Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
- Trial name
- NCT03854903
- Testing
- Palbociclib, Bosutinib, Fulvestrant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Georgetown University
Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
Our study is aimed to evaluate the efficacy and safety of novel ADC named SHR-A1921 combined with Adebrelimab in endocrine therapy-failed HR (Hormone Receptor)-positive, HER2-negative advanced breast cancer.
- Conditions
- Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- NCT06470672
- Testing
- SHR-A1921, Adebrelimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
The objective of this study is to evaluate the bioequivalence of a tablet formulation versus a capsule formulation of ASP8273 following a single dose under fasted condition in subjects with non-small cell lung cancer (NSCLC)…
- Trial name
- NCT03082300
- Testing
- naquotinib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
The purpose of this study is to assess the safety and tolerability of ASP8273 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).
- Trial name
- NCT02113813
- Testing
- naquotinib, midazolam
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
This study is divided into two parts: Cohort 1 and Cohort 2. Cohort 1 includes the dose escalation phase of DP303c combined with simmitinib, as well as the randomized controlled trial (RCT) phase of DP303c combined with…
- Conditions
- Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
- Trial name
- NCT06577376
- Testing
- DP303c, Simmitinib tablets, Irinotecan liposomes
- Volunteers
- 252 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to ≤ 3 OP lesions and continuation of first-line osimertinib, improves the median…
- Trial name
- LAT-FLOSI (NCT04216121)
- Testing
- Local ablative therapy
- Where
- Belgium
- Volunteers
- 39 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study
This was a non-interventional (observational), retrospective, cohort study of women with hormone receptor (HR)-positive and human epidermal growth factor receptor-type 2 (HER2)-negative advanced breast cancer who started…
- Trial name
- NCT06463626
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Novartis
Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor Mutation
Observational Study of Afatinib 30 mg Daily
Afatinib, a first-in-class irreversible ErbB family blocker, is a 1st line treatment option for patients with advanced stage NSCLC harbouring sensitizing EGFR mutations.
- Trial name
- NCT04909073
- Testing
- Afatinib
- Where
- Singapore
- Volunteers
- 69 people
- Sponsor
- National University Hospital, Singapore
Paronychia, Epidermal Growth Factor Receptor Inhibitor
Efficacy and Safety of Kinesiology Tape Wrapping for Paronychia Induced by Epidermal Growth Factor Receptor Inhibitors
Epidermal growth factor receptor inhibitors(EGFRIs) have been applied in several common malignancies including advanced non-small cell lung cancer.
- Trial name
- NCT06411093
- Testing
- Kinesiology tape wrapping, Conventional treatment including silver nitrate cauterization
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Chang Gung Memorial Hospital
Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.
Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of agents recently introduced in the clinic for the treatment of advanced hormone receptor-positive (HR+) and HER2-negative (HER2-) BC.
- Conditions
- Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer
- Trial name
- Palbociclib (NCT06338644)
- Testing
- Palbociclib
- Volunteers
- 100 people
- Sponsor
- Helwan University
Rash Due to Epidermal Growth Factor Receptor Inhibitors
A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI
Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic colorectal cancer patients. This study will prospectively accrue metastatic colorectal patients receiving EGFRI and treat with reconval cream…
- Trial name
- EGFRI (NCT01763307)
- Testing
- RECONVAL CREAM
- Volunteers
- 18 people
- Sponsor
- Hadassah Medical Organization